Merck's earnings call highlighted strong revenue growth, successful new product launches like GARDASIL, and reaffirmed positive 2008 guidance, all of which signal confidence in continued performance. While there are ongoing concerns with the VYTORIN ENHANCE trial, management's optimistic outlook and strategic initiatives are likely to reassure investors in the short term.

[1]